Streetbeat News

Products Services

BTCUSD

Ali Martinez, a technical and on-chain analyst, shared a dollar-cost averaging (DCA) strategy for Bitcoin investment on X (formerly Twitter). The strategy involves buying a fixed amount of Bitcoin at regular intervals, aiming to reduce the impact of market volatility. Martinez outlined steps for implementing this strategy and suggested specific buying points for Bitcoin based on its price. This approach is designed for long-term profitability despite potential short-term price pullbacks.

Portfolio Pulse from Khyathi Dalal

March 20, 2024 | 7:13 pm

RIO

Rio Tinto (NYSE:RIO) announced a $350 million investment in its Rincon lithium project in Argentina, aiming to expand the plant and support the EV market with high-quality lithium. This move highlights Argentina's growing role in the global lithium market, with the country's production increasing by 45% from 2022 to 2023. The Rincon project, part of the lithium-rich Salta province, aims for first lithium production by year's end, aligning with Rio Tinto's decarbonization goals.

Portfolio Pulse from Stjepan Kalinic

March 20, 2024 | 6:53 pm

CMPS

CYBN

MNMD

PSIL

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

DXCM

Benzinga's options scanner revealed significant trading activity on DexCom (NASDAQ:DXCM) options, with a focus on a price range of $97.5 to $131.0. The analysis of options trades, including both calls and puts, suggests a bullish sentiment among investors. DexCom, a company specializing in continuous glucose monitoring systems, has seen its stock price increase by 0.4% to $134.7. Analysts have set an average target price of $165.0 for DexCom, with RBC Capital downgrading its rating to Outperform.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 6:45 pm

NFLX

The options market shows a bearish sentiment towards Netflix (NASDAQ:NFLX), with 63% of trades being bearish. Major market movers are targeting a price range between $5.0 and $1100.0 for Netflix. Significant options trades have been detected, including both bearish and bullish positions. Netflix's business model focuses on its streaming service, with a global subscriber base of almost 250 million. The stock is currently down -0.15% at $619.81, with analysts setting an average price target of $694.0.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 6:45 pm

DHI

HD

LEN

LOW

The U.S. housing market is experiencing a mortgage lock-in issue, where high mortgage rates discourage homeowners from selling, contributing to a housing shortage and pushing prices up. Home development retailers like Home Depot Inc (HD) and Lowe's Companies Inc (LOW) have seen sales boosts due to homeowners opting to improve their current homes instead of moving. This situation pressures builders like D.R. Horton Inc (DHI) and Lennar Corporation (LEN) to increase new home construction. The Federal Housing Finance Agency reports that mortgage lock-in reduced home sales by 57% in Q4 2023, suggesting solutions like tax credits and mortgage portability to alleviate the issue.

Portfolio Pulse from Neil Dennis

March 20, 2024 | 6:29 pm

IGC

IGC Pharma (NYSE:IGC) announced promising interim results for their Alzheimer's drug, IGC-AD1, at Benzinga's Healthcare Summit. The drug, aimed at reducing agitation in Alzheimer's patients, shows potential in addressing both neuropsychiatric symptoms and the disease's underlying pathology by reducing amyloid plaques. IGC-AD1 demonstrated rapid effectiveness within two weeks and a favorable safety profile. The news led to a temporary trading halt of IGC's shares, underscoring market anticipation for this innovative treatment.

Portfolio Pulse from Abbey Higginbotham

March 20, 2024 | 6:02 pm

PAGS

PagSeguro Digital (NYSE:PAGS) has received mixed ratings from 6 analysts, with an upward trend in price targets, indicating a positive outlook. The company, a provider of financial technology solutions in Brazil, shows strong net margin and ROA but lags in ROE and revenue growth compared to peers. Analysts have adjusted their ratings and price targets, reflecting optimism about the company's future performance.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 6:01 pm

MSFD

MSFT

MSFU

Microsoft Corporation (NASDAQ:MSFT) is trading slightly higher, approaching its all-time high ahead of the Federal Reserve meeting. It's favored by investors on the r/investing subreddit for its cross-industry dominance and growth potential. The market's reaction to the Fed's policy statement could influence Microsoft's stock direction. Bullish traders can use Direxion Daily MSFT Bull 1.5X Shares (NASDAQ:MSFU) and bearish traders have Direxion Daily MSFT Bear 1X Shares (NASDAQ:MSFD) as options.

Portfolio Pulse from Melanie Schaffer

March 20, 2024 | 5:54 pm

JANX

Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc (NASDAQ:JANX), highlighting its TRACTr/TRACir platform's potential in targeting various tumor antigens and cancer types. The firm is optimistic about JANX's lead product, JANX007, for metastatic castration-resistant prostate cancer, projecting it could reach peak US sales of $1.3 billion by 2031. Despite early but compelling clinical data, JANX007 faces intense competition. Janux's strong financial position, with a cash balance of $344 million in 2023 and a recent capital raise of $296.5 million, supports the advancement of JANX007 and other programs. Cantor sets a price target of $100 for JANX, currently trading up 4.31% at $40.30.

Portfolio Pulse from Vandana Singh

March 20, 2024 | 5:44 pm